Arca
Skip to content

Appendicitis

Drug research and approvals for appendicitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 34 studies of appendicitis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 4 drug trials for it since 2013.

  • Recruiting worldwide: 34
  • Trials authorized in Canada: 4
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 34 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

2 approved, 1 in phase 3, 15 in phase 2, 2 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Tazobactam, Piperacillin

Doripenem
Phase 3 Bacterial penicillin-binding protein inhibitor
Metronidazole
Phase 2 DNA inhibitor
Bupivacaine
Phase 2 Sodium channel protein type IV alpha subunit blocker
Fosfomycin
Phase 2 UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor
Ertapenem
Phase 2 Bacterial penicillin-binding protein inhibitor
Ropivacaine
Phase 2 Sodium channel alpha subunit blocker
Sulfur hexafluoride
Phase 2 Diagnostic agent
Dexamethasone
Phase 2 Glucocorticoid receptor agonist
Cefuroxime
Phase 2 Bacterial penicillin-binding protein inhibitor
Ceftriaxone
Phase 2 Bacterial penicillin-binding protein inhibitor
Cefotaxime
Phase 2 Bacterial penicillin-binding protein inhibitor
Meropenem
Phase 2 Bacterial penicillin-binding protein inhibitor
Levofloxacin anhydrous
Phase 2 DNA gyrase inhibitor
Epinephrine
Phase 2 Adrenergic receptor agonist
Regramostim
Phase 2 Granulocyte colony stimulating factor receptor agonist
Ketamine
Early phase 1 Glutamate [NMDA] receptor negative allosteric modulator
Cefdinir
Early phase 1 Bacterial penicillin-binding protein inhibitor

How Its Trials Ended

363 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 72 whose ending is known, 54% met their primary endpoint, 6% missed it and 40% stopped early.

  • Completed, result not reported17247%
  • Ongoing6017%
  • Status unknown5916%
  • Met its primary endpoint3911%
  • Stopped: other or unclear164%
  • Stopped: enrollment or feasibility92%
  • Missed its primary endpoint41%
  • Stopped: lack of efficacy21%
  • Stopped: sponsor or business decision10%
  • Stopped: funding10%

Trials Authorized in Canada

Newest first; search them all in Canada trials
Apr 12, 2024Assessing the longitudinal outcomes of piperacillin/tazobactam versus ceftriaxone and metronidazole for children with perforated appendicitis (alpaca): a…metronidazole/ ceftriaxone/piperacillin-tazobactamMcmaster Childrens HospitalPending
Nov 1, 2023Intravenous ketorolac vs. morphine in children presenting with suspected appendicitis: study protocol for multicenter non-inferiority randomized controlled…Ketorolac / morphineGovernors Of The University Of CalgaryOngoing
Nov 25, 2020Intravenous ketorolac in children presenting with suspected appendicitis: a pilot single center randomised placebo controlled trial (keto-app)Ketorolac / morphineHamilton Health Sciences CorporationOngoing
May 4, 2015Metronidazole every 24 hours as part of triple antibiotic therapy for ruptured appendicitis in children managed operatively (metro): a noninferiority…MetronidazoleChildrens Hospital Of Eastern OntarioPending

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.